Constantine Lyketsos, MD
Psychiatry · Baltimore, MDNPI 1306881909
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,120 of the $45,039 with a category attached, or 66.9%. 9 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 34.8% of the total. Reporting peaked in 2019 at $15,664 and has fallen 63.9% since, to $5,658 in 2024. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $1407.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$16K
- Avanir Pharmaceuticals, Inc.$8K
- H. Lundbeck A S$5K
- AbbVie$4K
- E.r. Squibb & Sons, L.L.C.$4K
- GW Research Limited$3K
- plus $5K from 3 others
Across 4 payments — averaging $265,521 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Functional Neuromodulation Inc$1.1M
What the payments were for
- Consulting fees$30,12067%
- Speaking & faculty fees$3,6008%
- Travel & lodging$10,53623%
- Food & beverage$7822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 4 | $15,664 |
| Avanir Pharmaceuticals, Inc. | 8 | $8,080 |
| H. Lundbeck A S | 5 | $4,774 |
| AbbVie | 4 | $4,023 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,850 |
| GW Research Limited | 4 | $3,255 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $2,408 |
| Merck | 1 | $1,860 |
| Orion Corporation | 1 | $1,125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$15,664
- REXULTI$4,774
- CAPLYTA$2,408
How this compares
$45,039 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 12 | $34,552 |
| Memantine Hcl | 42 | $4,971 |
| Rivastigmine | 14 | $2,755 |
| Dronabinol | 11 | $1,772 |
| Donepezil Hcl | 58 | $769 |
| Escitalopram Oxalate | 37 | $607 |
| Sertraline Hcl | 21 | $344 |
| Bupropion XlBupropion Hcl | 14 | $319 |
| Methylphenidate Hcl | 22 | $277 |
| Nortriptyline Hcl | 26 | $253 |
| Trazodone Hcl | 11 | $108 |
| Clonazepam | 12 | $22 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Baltimore
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Akira SawaBaltimore$69K
- Paul RosenbergBaltimore$66K
- Adam KaplinBaltimore$62K
- Marc FishmanBaltimore$59K
- David NeubauerBaltimore$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.